Hello? Anyone out there? I send out a group email and get back scores of automated replies thanking me for my email and telling me when the recipient will be back in the office. I feel like the only person … Continue reading
It has been a while since providing an update on legislative proposals introduced in Congress that would impact the FDA, medical products and food industries. With Congress out on recess, it seemed like a good time to catch up on … Continue reading
It is another one of those questions – how did we get here? For months FDA’s DDMAC did not seem to understand the impact of social media, then asked for help understanding how to regulate it, then failed to produce … Continue reading
A break in the weather with cooling temps and a Congress out of session made Washington a more bearable place this week. Still, recovering from what has been the Bummer Summer may take a while and require some more salve. … Continue reading
Earlier this week, we examined the Warning and NOV letters that came from FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC). Today we’re going to look at a few of the communications lessons learned from same – and reminding … Continue reading
